BCRX
Price
$8.27
Change
-$0.00 (-0.00%)
Updated
Sep 5 closing price
Capitalization
1.74B
53 days until earnings call
DVAX
Price
$10.06
Change
+$0.08 (+0.80%)
Updated
Sep 5 closing price
Capitalization
1.18B
54 days until earnings call
Interact to see
Advertisement

BCRX vs DVAX

Header iconBCRX vs DVAX Comparison
Open Charts BCRX vs DVAXBanner chart's image
BioCryst Pharmaceuticals
Price$8.27
Change-$0.00 (-0.00%)
Volume$3.09M
Capitalization1.74B
Dynavax Technologies
Price$10.06
Change+$0.08 (+0.80%)
Volume$1.42M
Capitalization1.18B
BCRX vs DVAX Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. DVAX commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Buy and DVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (BCRX: $8.27 vs. DVAX: $10.06)
Brand notoriety: BCRX: Notable vs. DVAX: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BCRX: 103% vs. DVAX: 89%
Market capitalization -- BCRX: $1.74B vs. DVAX: $1.18B
BCRX [@Pharmaceuticals: Generic] is valued at $1.74B. DVAX’s [@Pharmaceuticals: Generic] market capitalization is $1.18B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 3 bearish.
  • DVAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than DVAX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а -0.48% price change this week, while DVAX (@Pharmaceuticals: Generic) price change was -0.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

DVAX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.74B) has a higher market cap than DVAX($1.18B). BCRX YTD gains are higher at: 9.973 vs. DVAX (-21.222). BCRX has higher annual earnings (EBITDA): 63.4M vs. DVAX (-34.26M). DVAX has more cash in the bank: 614M vs. BCRX (260M). DVAX has less debt than BCRX: DVAX (285M) vs BCRX (703M). BCRX has higher revenues than DVAX: BCRX (558M) vs DVAX (316M).
BCRXDVAXBCRX / DVAX
Capitalization1.74B1.18B147%
EBITDA63.4M-34.26M-185%
Gain YTD9.973-21.222-47%
P/E RatioN/A54.60-
Revenue558M316M177%
Total Cash260M614M42%
Total Debt703M285M247%
FUNDAMENTALS RATINGS
BCRX vs DVAX: Fundamental Ratings
BCRX
DVAX
OUTLOOK RATING
1..100
958
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
69
Overvalued
PROFIT vs RISK RATING
1..100
7885
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
6282
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for DVAX (69). This means that BCRX’s stock grew somewhat faster than DVAX’s over the last 12 months.

BCRX's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as DVAX (85). This means that BCRX’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's SMR Rating (95) in the Biotechnology industry is in the same range as BCRX (100). This means that DVAX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (62) in the Biotechnology industry is in the same range as DVAX (82). This means that BCRX’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (97) in the Biotechnology industry is in the same range as BCRX (100). This means that DVAX’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXDVAX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 4 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 25 days ago
79%
Bullish Trend 25 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 5 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APHDX23.23N/A
N/A
Artisan Global Discovery Institutional
PJERX15.29N/A
N/A
PGIM Jennison Global Equity Income R
PGKAX28.99N/A
N/A
PGIM Jennison Technology A
PLGIX18.14-0.04
-0.22%
Principal LargeCap Growth I Instl
DGAGX40.51-0.19
-0.47%
BNY Mellon Appreciation Investor

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with CRNX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
N/A
CRNX - BCRX
41%
Loosely correlated
+3.97%
ETNB - BCRX
39%
Loosely correlated
+3.02%
BEAM - BCRX
39%
Loosely correlated
+12.62%
ROIV - BCRX
38%
Loosely correlated
+2.78%
VKTX - BCRX
38%
Loosely correlated
+1.70%
More

DVAX and

Correlation & Price change

A.I.dvisor tells us that DVAX and BCRX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DVAX and BCRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+0.80%
BCRX - DVAX
32%
Poorly correlated
N/A
AMRX - DVAX
32%
Poorly correlated
+0.73%
ESPR - DVAX
32%
Poorly correlated
+5.93%
ALKS - DVAX
32%
Poorly correlated
+3.53%
SUPN - DVAX
29%
Poorly correlated
+1.25%
More